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Background-—New antiplatelet agents that provide greater, more consistent inhibition of the platelet ADP receptor P2Y12 may be
used in combination with glycoprotein (GP) IIb-IIIa antagonists, but their combined effect on platelet function and procoagulant
activity is not well studied. Therefore, the objective of this study was to evaluate the independent and complementary effects of
P2Y12 and GPIIb-IIIa inhibition on platelet function and procoagulant activity.
Methods and Results-—Healthy donor blood was treated with the active metabolite of prasugrel (R-138727 5 lmol/L), GPIIb-IIIa
antagonists (abciximab 3 lg/mL or eptiﬁbatide 0.9 lg/mL), and combinations thereof, exposed to physiologically relevant
agonists (collagen and ADP) and then evaluated for markers of platelet activation and procoagulant activity. Signiﬁcant interactions
between R-138727 and GPIIb-IIIa antagonists were observed. R-138727 and the GPIIb-IIIa antagonists had additive inhibitory
effects on collagen-stimulated platelet aggregation and on the collagen plus ADP–stimulated level of activated platelet surface
GPIIb-IIIa. R-138727 and abciximab each inhibited collagen plus ADP–stimulated platelet phosphatidylserine expression and
prothrombin cleavage, and the combination produced greater inhibition than achieved with abciximab alone. In contrast,
eptiﬁbatide did not inhibit, but instead enhanced, collagen plus ADP–stimulated prothrombin cleavage. Addition of
R-138727 reduced prothrombin cleavage in eptiﬁbatide-treated samples, suggesting a novel mechanism for potential beneﬁt
from combined prasugrel and eptiﬁbatide treatment.
Conclusions-—The complementary effects of abciximab and R-138727 on platelet activation, aggregation, and procoagulant
activity suggest their combined use may, to a greater degree than with either agent alone, reduce thrombus formation in vivo.
(J Am Heart Assoc. 2013;2:e000026 doi: 10.1161/JAHA.113.000026)
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I
n addition to the most commonly used antiplatelet agent,
aspirin, which inhibits platelet cyclooxygenase-1, two
distinct classes of antiplatelet agents with distinct mecha-
nisms of action, glycoprotein (GP) IIb-IIIa antagonists (eg,
abciximab, eptiﬁbatide) and antagonists of the platelet ADP
receptor P2Y12 (eg, clopidogrel, prasugrel), are used for the
prevention of cardiac ischemic complications in the setting of
percutaneous coronary intervention (PCI).
1,2 Abciximab is the
Fab fragment of the chimeric human–murine monoclonal
antibody 7E3, whereas eptiﬁbatide is a cyclic hexapeptide,
small-molecule inhibitor.
3 Abciximab and eptiﬁbatide bind to
the GPIIb-IIIa (integrin aIIbb3) receptor of human platelets,
inhibiting the ﬁnal common pathway of platelet aggregation in
response to all agonists. Clopidogrel and prasugrel are
thienopyridine prodrugs, each with an active metabolite that
irreversibly inhibits the platelet ADP receptor P2Y12 and,
thereby, inhibits ADP-induced platelet activation and aggre-
gation.
1
While aspirin plus clopidogrel is the most frequently orally
administered antiplatelet combination in PCI,
4 novel P2Y12
inhibitors such as ticagrelor and prasugrel are also used in the
setting of acute coronary syndrome PCI.
5 As GPIIb-IIIa and
P2Y12 antagonists target distinct steps of the thrombus
formation process, supplementing aspirin plus P2Y12 antag-
onist therapy with a GPIIb-IIIa antagonist enhances platelet
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ularly patients with large thrombus burden or poor response
to oral antiplatelet agents.
2,4,6 Although combination GPIIb-IIIa
and P2Y12 inhibition on an aspirin background is used in the
clinical setting, the combined effect of these inhibitors on
platelet responses has not been well studied, particularly in
the case of the newer P2Y12 agents.
In in vitro studies, the active metabolite of prasugrel,
R-138727, in the absence or presence of aspirin, inhibits
platelet activation as well as platelet procoagulant and
proinﬂammatory responses;
7–9 however, the effect of concom-
itantprasugrelandGPIIb-IIIaantagonisttreatmentontheseend
points remains unknown. Therefore, the objective of this study
was to evaluatethe independent and complementary effects of
P2Y12 and GPIIb-IIIa inhibition on platelet function. On a
background of aspirin, we evaluated the combined effect of in
vitro treatment of whole blood with the active metabolite of
prasugrel, R-138727, plus abciximab or eptiﬁbatide on platelet
activation, aggregation, and procoagulant activity.
Methods
Materials
ADP was purchased from Bio/Data Corporation, and ﬁbrillar
type I collagen was purchased from Chrono-log. Gly-Pro-Arg-
Pro (GPRP) was purchased from Bachem. The ﬂuorogenic
activated factor XIII (FXIIIa) substrate was from Zedira.
Fluorescein isothiocyanate (FITC)-conjugated annexin V,
FITC-labeled PAC1 (an IgM monoclonal antibody [mAb] speciﬁc
for the activated conformation of GPIIb-IIIa), phycoerythrin
(PE)-Cy5–conjugated CD42b-speciﬁc mAb, and PE-conjugated
CD42a- and CD62P-speciﬁc mAbs were from Becton Dickin-
son. PE-Cy5–labeled CD14-speciﬁc mAb was from Beckman
Coulter. FITC-conjugated anti–tissue factor mAb (clone VD8)
was from American Diagnostica. Puriﬁed human coagulation
factors Va and Xa (FVa and FXa, respectively) were purchased
from Haematologic Technologies. The prothrombin fragment
1.2 (F1.2) ELISA was from Dade Behring.
Blood Collection and Treatment
Institutional review board–approved written informed consent
was obtained from all subjects. Two hours after healthy
volunteers ingested aspirin 325 mg (Bayer HealthCare), blood
was collected into a ﬁnal concentration of sodium citrate
0.32%, hirudin 25 lg/mL, or D-Phe-Pro-Arg-chloromethylke-
tone 300 lmol/L (PPACK; EMD Biosciences). Platelet counts
for all donors were within the normal range of 150 to
400910
3/lL. R-138727 (provided by Daiichi Sankyo Com-
pany Ltd, Tokyo, Japan) was dissolved in DMSO and kept at
80°C in sealed vials. Immediately before use, R-138727 was
diluted in HEPES 10 mmol/L, NaCl 0.15 mol/L, pH 7.4
(HEPES-saline). For all subsequent assays, whole blood
was incubated for 30 minutes at 37°C with R-138727
5 lmol/L, abciximab 3.0 lg/mL (ReoPro; Centocor), eptiﬁ-
batide 0.9 lg/mL (Integrilin; Millennium Pharmaceuticals),
R-138727 5 lmol/L plus abciximab 3.0 lg/mL, R-138727
5 lmol/L plus eptiﬁbatide 0.9 lg/mL, or vehicle (DMSO
diluted identically to R-138727). R-138727, abciximab, and
eptiﬁbatide concentrations used for these experiments were
selected to correspond with the level of platelet inhibition
achieved in patients treated with the current recommended
dosing regimens: prasugrel at 60 mg loading dose and
10 mg/day maintenance dose;
10 abciximab at 0.25 mg/kg
intravenous bolus followed by continuous infusion of
0.125 lg/kg per minute;
11 eptiﬁbatide at 180 lg/kg intra-
venous bolus followed immediately by a continuous infusion
of 2.0 lg/kg per minute and a second eptiﬁbatide bolus of
180 lg/kg administered 10 minutes later.
12 Concentrations
of R-138727, abciximab, and eptiﬁbatide were calculated with
respect to the plasma compartment of the blood to account
for differences in hematocrit between donors. For selected
experiments, platelet-rich plasma (PRP) was prepared by
centrifugation of treated whole blood for 10 minutes at 150g.
For each assay subsequently described, 6 independent
experiments were performed using blood collected from 6
different donors.
Platelet Aggregometry
Light transmission platelet aggregation was evaluated in a
Chrono-log aggregometer in PPACK-anticoagulated PRP in
response to ADP 20 lmol/L or collagen 20 lg/mL. The
aggregation response was recorded for a total of 6 minutes
using Aggro/Link software (Chrono-log). Platelet counts were
not adjusted before the use of PRP in aggregation.
Platelet Surface Expression of Activated GPIIb-IIIa
and P-selectin
PPACK-anticoagulated whole blood was incubated with FITC-
PAC1, PE anti-CD62P, and PE-Cy5 anti-CD42a (as a platelet
identiﬁer) and either collagen 20 lg/mL plus ADP 20 lmol/L
or no agonist (HEPES-Tyrode’s buffer) for 15 minutes at room
temperature. Samples were then ﬁxed by addition of 1%
formaldehyde in HEPES-saline. Flow cytometric analysis was
performed in a calibrated Becton Dickinson FACSCalibur as
previously described.
13
Platelet Surface Binding of Annexin V
PPACK-anticoagulated whole blood was diluted 1:10 in HEPES-
Tyrode’s buffer and incubated with collagen 20 lg/mL plus
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20 minutes at 37°C. Phosphatidylserine expression on the
platelet surface was determined by annexin V binding as
previously described.
8 Brieﬂy, after incubation with collagen
plus ADP or buffer, samples were mixed with FITC-conjugated
annexin V and a PE-Cy5 anti-CD42a antibody (as a platelet
identiﬁer) in the presence of CaCl2 4 mmol/L, incubated for
15 minutes at room temperature, and ﬁxed with 1% formal-
dehyde in HEPES-saline. Flow cytometric analysis was per-
formed in a calibrated Becton Dickinson FACSCalibur.
Tissue Factor Expression on Monocyte–Platelet
Aggregates and Single Platelets
The presence of monocyte–platelet aggregates and the
expression of tissue factor on monocyte–platelet aggregates
and single platelets were detected, as previously described,
14
in PPACK-anticoagulated whole blood stimulated with
collagen 20 lg/mL plus ADP 20 lmol/L or no agonist
(HEPES-saline). In brief, whole blood was incubated with
agonists for 15 minutes at room temperature and then
incubated with a mixture of PE anti-CD42a 1 lg/mL for
platelet identiﬁcation, PE-Cy5 anti-CD14 for monocyte
identiﬁcation, and FITC-conjugated anti–tissue factor mAb
10 lg/mL for 20 minutes at room temperature. After incu-
bation, FACS Lysing solution (Becton Dickinson) was added to
samples, and ﬂow cytometric analysis was performed in a
Becton Dickinson FACSCalibur.
Thrombin Generation
Hirudin-anticoagulated whole blood was mixed for 15 minutes
at 37°C with shaking with FXa 600 pmol/L and FVa
300 pmol/L combined with either collagen 20 lg/mL plus
ADP 20 lmol/L or no agonist (HEPES-Tyrode’s buffer) in a
96-well microtiter plate (total volume 100 lL, all concentra-
tions are ﬁnal concentrations in whole blood). The assay was
stopped by the addition of 260 lL of EDTA 2 mmol/L in
HEPES-saline. Samples were centrifuged and thrombin gen-
eration was measured by the formation of F1.2 in the
supernatant using the Enzygnost F1.2 ELISA.
Activated FXIII Generation
For FXIII assays, blood was collected from healthy volunteers
into sodium citrate, 24 hours after ingestion of aspirin
325 mg. As described earlier, blood was treated with
R-138727, abciximab, and eptiﬁbatide, and PRP was prepared
via centrifugation. Sodium citrate–anticoagulated PRP was
combined with FXIIIa substrate solution (ﬂuorogenic FXIIIa
substrate 56 lmol/L, CaCl2 20 mmol/L, FXa 60 pmol/L, FVa
30 pmol/L, and GPRP 10 mmol/L) and collagen 20 lg/mL
plus ADP 20 lmol/L or no agonist (HEPES-saline) in a 96-well
microtiter plate (all concentrations are ﬁnal concentrations in
PRP). Fluorescence was monitored (excitation at 313 nm and
emission at 418 nm) in a microtiter plate reader for
45 minutes at 37°C with shaking. PPACK-treated PRP was
used as the plate blank.
Statistical Methods
Data analyses were performed by the authors using GraphPad
Prism Version 5.0 and VassarStats: Website for Statistical
Computation.
15 Data are presented as meanSEM from 6
independent experiments. The effects of R-138727, the GPIIb-
IIIa antagonists, and the interactions between R-138727 and
the GPIIb-IIIa antagonists were determined by 2-factor
repeated measures ANOVA (RM-ANOVA) with P<0.05 consid-
ered statistically signiﬁcant. Posttests to compare individual
treatment conditions assumed samples were from normal
distributions andwerebyStudent’spairedttestorby1-sample
t test (for comparison with a normalized baseline result). To
account for multiple comparisons, only posttest P values
<0.0071 (Bonferroni correction) were considered signiﬁcant.
Results
Inhibition of Platelet Aggregation by P2Y12 and
GPIIb-IIIa Antagonists
The P2Y12 antagonist R-138727 has been previously shown to
dose-dependently inhibit ADP-induced platelet aggregation.
7
To investigate the combined effect of P2Y12 and GPIIb-IIIa
inhibition on a background of aspirin, platelet aggregation was
studied in PRP from aspirin-treated subjects, treated in vitro
with R-138727 alone or in combination with the GPIIb-IIIa
antagonists, abciximab or eptiﬁbatide. Consistent with previ-
ous studies, when platelets were stimulated with ADP,
aggregation was signiﬁcantly inhibited in the presence of
R-138727 (Figure 1). Likewise, as expected, treatment with
either GPIIb-IIIa antagonist resulted in a marked decrease in
ADP-induced aggregation. However, the addition of either
abciximab or eptiﬁbatide to R-138727 completely abrogated
platelet aggregation (Figure 1). Two-factor RM-ANOVA of
ADP-induced platelet aggregation (Table) showed a signiﬁcant
effect of both R-138727 (P<0.0001) and the GPIIb-IIIa
antagonists (P<0.0001) and a signiﬁcant interaction between
R-138727 and the GPIIb-IIIa antagonists (P=0.0009). When
collagen was used as the agonist, the presence of R-138727
resulted in a smaller, but still signiﬁcant, decrease in maximal
platelet aggregation (Figure 1). As with ADP-induced aggre-
gation, the GPIIb-IIIa antagonists signiﬁcantly inhibited colla-
gen-induced platelet aggregation compared with vehicle.
Combined treatment with R-138727 plus abciximab or
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Heptiﬁbatide resulted in a markedly reduced aggregation
responsecomparedwithR-138727treatmentalone(Figure 1).
Furthermore, when R-138727 was added to the GPIIb-IIIa
antagonists, platelet aggregation was decreased beyond the
level of aggregation with GPIIb-IIIa inhibition alone.
Platelet Surface Activated GPIIb-IIIa and
P-selectin
Because platelet aggregation is dependent on the activation
of GPIIb-IIIa,
16 the combined effect of P2Y12 and GPIIb-IIIa
inhibition on the expression and availability of activated GPIIb-
IIIa was evaluated in whole blood treated with R-138727 alone
or in combination with abciximab or eptiﬁbatide. After
stimulation with collagen plus ADP, platelet surface activated
GPIIb-IIIa expression, as reﬂected by mAb PAC1 binding, was,
as expected, markedly increased compared with unstimulated
samples (Figure 2A). R-138727 treatment caused a substan-
tial reduction in the level of surface activated GPIIb-IIIa. The
presence of either GPIIb-IIIa antagonist signiﬁcantly reduced
PAC1 binding to activated GPIIb-IIIa in collagen plus ADP–
stimulated samples (Figure 2A). PAC1 binding was further
inhibited when R-138727 was added to abciximab- or
eptiﬁbatide-treated samples, and combined GPIIb-IIIa and
P2Y12 antagonism resulted in signiﬁcant inhibition beyond
R-138727 treatment alone (Figure 2A). In unstimulated (no
agonist) samples with low baseline activated GPIIb-IIIa, PAC1
binding was reduced by either GPIIb-IIIa inhibitor and, more
signiﬁcantly, inhibited by the combination of R-138727 plus
abciximab or eptiﬁbatide (Figure 2A).
Table. Statistical analysis of platelet activation, aggregation,
and procoagulant responses to ADP 20 lmol/L and collagen
20 lg/mL in the presence of R-138727 5 lmol/L, abciximab
3 lg/mL,oreptiﬁbatide0.9 lg/mL,andcombinationsthereof
Factor P Value
Platelet aggregation—ADP
(maximum % aggregation)
R-138727 <0.0001
GPIIb-IIIa antagonists <0.0001
Interaction 0.0009
Platelet aggregation—collagen
(maximum % aggregation)
R-138727 0.0021
GPIIb-IIIa antagonists <0.0001
Interaction 0.3960
Activated GPIIb-IIIa—collagen
+ADP (PAC1 MFI)
R-138727 <0.0001
GPIIb-IIIa antagonists <0.0001
Interaction <0.0001
Platelet surface
P-selectin—collagen+ADP
(MFI)
R-138727 0.0012
GPIIb-IIIa antagonists 0.0131
Interaction 0.0223
% MPAs—collagen+ADP R-138727 0.0008
GPIIb-IIIa antagonists 0.0014
Interaction 0.0004
Platelet ﬂuorescence in
MPAs—collagen+ADP (MFI)
R-138727 0.0006
GPIIb-IIIa antagonists 0.0002
Interaction 0.0001
% Annexin V–positive
platelets—collagen+ADP
R-138727 0.0010
GPIIb-IIIa antagonists <0.0001
Interaction <0.0001
MPA tissue
factor—collagen+ADP (MFI)
R-138727 0.0007
GPIIb-IIIa antagonists <0.0001
Interaction 0.0001
Platelet tissue
factor—collagen+ADP (MFI)
R-138727 <0.0001
GPIIb-IIIa antagonists 0.2341
Interaction 0.0012
Plasma F1.2—collagen+ADP
(normalized)
R-138727 0.0002
GPIIb-IIIa antagonists 0.0102
Interaction 0.0183
Relative FXIIIa
activity—collagen+ADP
(1/time to Vmax, normalized)
R-138727 0.3542
GPIIb-IIIa antagonists 0.0136
Interaction 0.8089
Two-factor ANOVA with repeated measures on both factors. GP indicates glycoprotein;
MFI, mean ﬂuorescence intensity; MPA, monocyte–platelet aggregate; Vmax, maximum
velocity.
Figure 1. Effect of combined P2Y12 and GPIIb-IIIa inhibition on
ADP- or collagen-induced platelet aggregation. Platelet-rich plasma
(PRP) was prepared from PPACK-anticoagulated blood treated with
vehicle or R-138727 5 lmol/L in the absence or presence of
abciximab 3 lg/mL or eptiﬁbatide 0.9 lg/mL. PRP was stimulated
with ADP 20 lmol/L or collagen 20 lg/mL and the extent of
platelet aggregation was determined. Data are reported as mean
SEM from 6 experiments. *P<0.0071 vs no R-138727, vehicle
treatment;
+P<0.0071 vs corresponding treatment in the absence of
R-138727;
#P<0.0071 vs R-138727, vehicle treatment. GP indicates
glycoprotein; PPACK, D-Phe-Pro-Arg-chloromethylketone.
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HTo further assess the level of platelet activation with
combined P2Y12 and GPIIb-IIIa inhibition, we evaluated the
platelet surface expression of P-selectin. Two-factor RM-
ANOVA of collagen plus ADP–stimulated platelet surface
P-selectin (Table) showed a signiﬁcant effect of R-138727
(P=0.0012), the GPIIb-IIIa antagonists (P=0.0131), and a
signiﬁcant interaction between R-138727 and the GPIIb-IIIa
antagonistswaspresent(P=0.0223).R-138727causedalarge,
signiﬁcant decrease (95%, P=0.0011, paired t test) in platelet
surface P-selectin expression in collagen plus ADP–stimulated
blood (Figure 2B); a smaller, signiﬁcant decrease (19%,
P=0.0067, paired t test) was observed with abciximab. No
change in collagen plus ADP–stimulated P-selectin expression
was observed in the presence of eptiﬁbatide. When abciximab
or eptiﬁbatide was used in combination with R-138727, the
decrease in P-selectin expression was comparable to that
observed with only R-138727 treatment (Figure 2B).
Monocyte–Platelet Aggregates
As an additional marker of the level of platelet activation with
combined P2Y12 and GPIIb-IIIa inhibition, monocyte–platelet
aggregates were measured with and without collagen plus
ADP stimulation. In the absence of antiplatelet agents, as
expected, collagen plus ADP increased the percentage of
monocytes bound to platelets (monocyte–platelet aggregates)
and the platelet ﬂuorescence in monocyte–platelet aggre-
gates (Figure 3A and 3B). By 2-factor RM-ANOVA, R-138727,
GPIIb-IIIa antagonists, and the interaction between R-138727
and GPIIb-IIIa antagonists were highly signiﬁcant for the
collagen plus ADP–stimulated percentage of monocyte–
platelet aggregates and the platelet ﬂuorescence in
monocyte–platelet aggregates (Table). In collagen plus
ADP–stimulated samples, R-138727 reduced the percentage
of monocyte–platelet aggregates and the level of platelet
ﬂuorescence in the aggregates, indicating a reduced number
of platelets in the aggregates (Figure 3). Although abciximab
and eptiﬁbatide each resulted in numerical increases in the
percentage of monocyte–platelet aggregates and platelet
ﬂuorescence in monocyte–platelet aggregates, in posttests,
only the abcximab-induced increase in platelet ﬂuorescence
remained statistically signiﬁcant. Addition of R-138727 to
abciximab abrogated this increase, reducing platelet ﬂuores-
cence in monocyte–platelet aggregates to the level observed
with R-138727 treatment alone (Figure 3).
Platelet Surface Expression of Phosphatidylserine
In addition to their role in aggregate formation, activated
platelets promote coagulation through surface exposure of
procoagulant phosphatidylserine.
17 As expected, stimulation
with collagen plus ADP increased the percentage of annexin
V–positive platelets (Figure 4). Two-factor RM-ANOVA analy-
sis (Table) showed a signiﬁcant effect of both R-138727
(P=0.0010) and the GPIIb-IIIa antagonists (P<0.0001) and a
signiﬁcant interaction between R-138727 and the GPIIb-IIIa
antagonists (P<0.0001). Individual treatment with R-138727
or abciximab reduced annexin V binding in collagen plus ADP–
stimulated samples (annexin V–positive platelets 22.92.7%
with vehicle versus 9.51.6% for R-138727, P=0.0004, and
14.71.9% for abciximab, P=0.0004), but no signiﬁcant effect
was observed with eptiﬁbatide (P=0.0247 versus vehicle;
nonsigniﬁcant with Bonferroni correction). No further inhibi-
Figure 2. Inhibition of platelet surface expression of activated
GPIIb-IIIa and P-selectin by R-138727 plus abciximab or eptiﬁbatide.
PPACK-anticoagulated whole blood treated with R-138727, abcix-
imab, or eptiﬁbatide, and combinations thereof, was incubated with
collagen 20 lg/mL plus ADP 20 lmol/L or no agonist and labeled
with ﬂuorescently-conjugated antibodies for analysis by whole blood
ﬂow cytometry. A, Platelet surface activated GPIIb-IIIa, as determined
by platelet binding of the monoclonal antibody PAC1 (mean
ﬂuorescence intensity). B, Platelet surface expression of P-selectin
(mean ﬂuorescence intensity). Data are shown as meanSEM, n=6.
*P<0.0071 vs no R-138727, vehicle treatment;
+P<0.0071 vs
corresponding treatment in the absence of R-138727;
#P<0.0071
vs R-138727, vehicle treatment. GP indicates glycoprotein; PPACK,
D-Phe-Pro-Arg-chloromethylketone.
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R-138727 treatment (Figure 4).
Tissue Factor Expression on Monocyte–Platelet
Aggregates and Individual Platelets
Beyond platelet surface expression of phosphatidylserine,
platelets and monocyte–platelet aggregates can stimulate
coagulation through surface expression of tissue factor. In
previous studies, treatment with R-138727 decreased the
level of tissue factor on monocyte–platelet aggregates.
8 To
extend these studies, we investigated the effect of R-138727
combined with abciximab or eptiﬁbatide on procoagulant
surface expression of tissue factor. Stimulation with collagen
plus ADP increased the level of tissue factor ﬂuorescence on
both monocyte–platelet aggregates and single platelets
(Figure 5A and 5B). Two-factor RM-ANOVA analysis of tissue
factor on monocyte–platelet aggregates (Table) showed
signiﬁcant effects of R-138727 (P=0.0007), GPIIb-IIIa antag-
onists (P<0.0001), and the interaction between R-138727 and
GPIIb-IIIa antagonists (P=0.0001). Tissue factor on monocyte–
platelet aggregates induced by collagen plus ADP was
reduced by R-138727 (Figure 5A). In parallel to the increase
in monocyte–platelet aggregates observed with abciximab or
eptiﬁbatide (Figure 3), individual treatment with either GPIIb-
IIIa antagonist caused an increase in monocyte–platelet tissue
factor (Figure 5A). The addition of R-138727 to abciximab or
eptiﬁbatide reduced tissue factor levels on monocyte–platelet
aggregates. When tissue factor on individual platelets stim-
ulated with collagen plus ADP was examined, R-138727
treatment caused signiﬁcant inhibition, while the GPIIb-IIIa
antagonists had no signiﬁcant effect (2-factor RM-ANOVA
R-138727, P<0.0001; GPIIb-IIIa antagonists, P=0.2341; Table)
on platelet tissue factor (Figure 5B).
Platelet-Dependent Coagulation Factor
Activation: F1.2 Generation and FXIIIa Activity
To determine the effects of combined platelet P2Y12 and GPIIb-
IIIa inhibition on coagulation, we investigated platelet-depen-
dent enhancement of thrombin generation and activation of
Figure 4. Effect of R-138727 in combination with abciximab or
eptiﬁbatide on platelet surface phosphatidylserine exposure. Surface
exposure of phosphatidylserine was determined ﬂow cytometrically
by annexin V binding of platelets from PPACK-anticoagulated blood
incubated with collagen 20 lg/mL plus ADP 20 lmol/L or no
agonist. Data are shown as the percentage of platelets positive for
annexin V staining, meanSEM, n=6. *P<0.0071 vs no R-138727,
vehicle treatment;
+P<0.0071 vs corresponding treatment in the
absence of R-138727;
#P<0.0071 vs R-138727, vehicle treatment.
PPACK indicates D-Phe-Pro-Arg-chloromethylketone.
Figure 3. ADP plus collagen-induced monocyte–platelet aggre-
gates in the presence of P2Y12 and GPIIb-IIIa antagonists. Whole
blood anticoagulated with PPACK was stimulated with collagen
20 lg/mL plus ADP 20 lmol/L or no agonist, ﬂuorescently-labeled
for monocytes and platelets, and analyzed ﬂow cytometrically. A,
Percentage of monocytes with platelet attached. B, Platelet ﬂuores-
cence (mean ﬂuorescence intensity) in monocyte–platelet aggre-
gates. Results are meanSEM (n=6). *P<0.0071 vs no
R-138727, vehicle treatment;
+P<0.0071 vs corresponding treatment
in the absence of R-138727;
#P<0.0071 vs R-138727, vehicle
treatment. GP indicates glycoprotein; PPACK, D-Phe-Pro-Arg-chlo-
romethylketone.
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tide. When thrombin generation was measured by the
formation of F1.2 in whole blood, addition of collagen plus
ADP, in the presence of priming concentrations of FVa and
FXa, caused a marked increase in F1.2 compared with blood
primed with FVa and FXa but without the addition of collagen
plus ADP (Figure 6). Two-factor RM-ANOVA (Table) showed a
signiﬁcant effect of R-138727 (P=0.0002) and the GPIIb-IIIa
antagonists (P=0.0102) and a signiﬁcant interaction between
R-138727 and the GPIIb-IIIa antagonists (P=0.0183). Collagen
plus ADP–enhanced F1.2 levels were reduced by 38% by
R-138727 treatment compared with vehicle (P=0.0064,
1-sample t test, Figure 6). Treatment with abciximab alone
reduced the collagen plus ADP–dependent increase in F1.2
(P=0.0250, 1-sample t test), while eptiﬁbatide treatment
enhanced collagen plus ADP–stimulated F1.2 (P=0.0482,
1-sample t test), although neither effect reached statistical
signiﬁcance after Bonferroni correction. The combination of
R-138727 plus abciximab or eptiﬁbatide reduced F1.2 com-
pared with individual GPIIb-IIIa antagonist treatment and
resulted in a level of F1.2 that was comparable to R-138727
treatment alone (Figure 6).
FXIIIa generation, primed by addition of FVa and FXa, was
signiﬁcantly increased by platelet activation with collagen plus
ADP (Figure 7). Relative FXIIIa activity in collagen plus ADP–
activated samples was not signiﬁcantly affected by treatment
with R-138727 or eptiﬁbatide alone (Figure 7). However, the
relative FXIIIa activity was signiﬁcantly, albeit modestly,
decreased in the presence of abciximab (P=0.0015, 1-sample
t test, Figure 7).
Discussion
The main ﬁndings of this study are as follows. (1) The
combination of P2Y12 and GPIIb-IIIa antagonists, at whole
blood concentrations that demonstrate pharmacological
Figure 5. Tissue factor expression on monocyte–platelet aggre-
gates (MPAs) and individual platelets in the presence of R-138727
plus abciximab or eptiﬁbatide. MPAs and individual platelets from
PPACK-anticoagulated blood stimulated with collagen 20 lg/mL
plus ADP 20 lmol/L or no agonist were stained with an anti-tissue
factor antibody and analyzed ﬂow cytometrically. A, Tissue factor on
MPAs (ﬂuorescence, arbitrary units). B, Tissue factor on individual
platelets (ﬂuorescence, arbitrary units). Results are reported as
meanSEM from 6 independent experiments. *P<0.0071 vs no
R-138727, vehicle treatment;
+P<0.0071 vs corresponding treatment
in the absence of R-138727;
#P<0.0071 vs R-138727, vehicle
treatment. PPACK indicates D-Phe-Pro-Arg-chloromethylketone.
Figure 6. Inhibition of P2Y12 and GPIIb-IIIa in platelet-dependent
thrombin generation. Hirudin-anticoagulated blood was incubated
with FXa 600 pmol/L and FVa 300 pmol/L with collagen 20 lg/mL
plus ADP 20 lmol/L or with buffer. Thrombin generation was
determined by the level of prothrombin fragment F1.2 as measured
by ELISA. Results shown are normalized per subject to collagen plus
ADP with no-R138727, vehicle treatment; meanSEM, n=6.
*P<0.0071 vs no R-138727, vehicle treatment;
+P<0.0071 vs
corresponding treatment in the absence of R-138727;
#P<0.0071
vs R-138727, vehicle treatment. GP indicates glycoprotein; FVa and
FXa, coagulation factors Va and Xa, respectively.
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induced platelet aggregation and collagen plus ADP–induced
platelet surface activated GPIIb-IIIa than with either antago-
nist alone (Figures 1 and 2A). (2) The level of tissue factor on
monocyte–platelet aggregates was increased by GPIIb-IIIa
inhibitors, and the increase was signiﬁcantly reduced by the
active metabolite of prasugrel, R-138727 (Figure 5A). (3)
R-138727 and abciximab each signiﬁcantly inhibited collagen
plus ADP–stimulated platelet surface expression of phospha-
tidylserine (Figure 4) and reduced thrombin generation
(Figure 6). In contrast, eptiﬁbatide alone increased, albeit
modestly, platelet activation–dependent thrombin generation
(Figure 6). The combination of R-138727 with eptiﬁbatide
reduced the level of thrombin generation to that seen with
R-138727 alone. (4) Abciximab, but not eptiﬁbatide, reduced
FXIIIa activation downstream from platelet activation with
collagen plus ADP (Figure 7).
Clinical Evidence Suggesting a Beneﬁt From
Combined GPIIb-IIIa and P2Y12 Inhibition
The presently described additive effects of GPIIb-IIIa antago-
nists and prasugrel’s active metabolite on platelet activation,
aggregation, and procoagulant activities have not previously
been reported. While current indications for GPIIb-IIIa antag-
onist use are limited,
3,18 broader application of GPIIb-IIIa
antagonists in combination with P2Y12 antagonists may have
clinical beneﬁt. For example, when prasugrel was administered
withorwithouttheGPIIb-IIIaantagonisttiroﬁbaninST-segment
elevation acute myocardial infarction patients on aspirin,
platelet inhibition was suboptimal (as measured by ADP-
induced aggregation) for at least 2 hours with prasugrel alone,
but the addition of tiroﬁban led to a signiﬁcantly higher degree
of platelet inhibition.
6 Furthermore, a recent meta-analysis of
randomized trials of patients undergoing elective PCI with
stents and periprocedural thienopyridines, assigned to
randomly receive a GPIIb-IIIa antagonist or control, show a
clinical beneﬁt of GPIIb-IIIa inhibitors (both abciximab and
small-molecule inhibitors).
2 Speciﬁcally, GPIIb-IIIa antagonists
added on a background of aspirin and a thienopyridine were
shown to reduce nonfatal myocardial infarction, without an
increase in major bleeding, but with an increase in minor
bleeding. These studies combined with the present study
suggest that GPIIb-IIIa antagonists are beneﬁcial in inhibiting
platelet function when used in combination with P2Y12
antagonists.
Augmented Inhibition of Platelet Activation,
Aggregation, and Procoagulant Activities by
Combined Use of R-138727 and GPIIb-IIIa
Antagonists
Because light transmission platelet aggregation has been the
de facto gold standard for platelet function testing throughout
the development of the GPIIb-IIIa antagonists and newer P2Y12
antagonists,
19 the additive inhibitory effect of R-138727 plus
abciximab or eptiﬁbatide on collagen– and ADP–stimulated
platelet aggregation is not surprising. The additional inhibition
of platelet aggregation and platelet surface activated GPIIb-IIIa
expression by combined P2Y12 and GPIIb-IIIa antagonists may
in part explain the clinical beneﬁt resulting from their
combined use in the meta-analysis described earlier.
2 Down-
stream effects of combined inhibition with abciximab and R-
138727 observed in the present study [reduced annexin V–
positive platelets (Figure 4) and reduced conversion of
prothrombin to thrombin with concomitant release of F1.2
(Figure 6)] are also likely to be mechanistically linked to the
clinical beneﬁt observed in the meta-analysis.
2 The results of
the present study are similar to that reported for the
combination of cangrelor, a reversible P2Y12 antagonist and
abciximab or tiroﬁban, which resulted in additive inhibition of
platelet aggregate formation, dense granule secretion, soluble
CD40 ligand release, annexin V binding, and procoagulant
microparticle formation, and to a study of in vivo clopidogrel
plus in vitro GPIIb-IIIa inhibition that demonstrated additive
Figure 7. Platelet-dependent FXIIIa generation in the presence of
R-138727 plus abciximab or eptiﬁbatide. Sodium citrate–anticoagu-
latedbloodwasincubatedwithsolutionofCaCl2,GPRP(toinhibitﬁbrin
polymerization), FXa 60 pmol/L, and FVa 30 pmol/L combined with
collagen 20 lg/mL plus ADP 20 lmol/L or no agonist. FXIIIa
generation was monitored by the cleavage of a ﬂuorogenic FXIIIa
substrate,andtherelativeFXIIIaactivitywasreportedasthereciprocal
ofthetimetoreachVmax,normalizedpersubjectbythevalueobtained
foravehicle-treatedsamplestimulatedwithcollagenplusADP.Results
are meanSEM, from 6 experiments. *P<0.0071 vs no R-138727,
vehicle treatment;
+P<0.0071 vs corresponding treatment in the
absence of R-138727;
#P<0.0071 vs R-138727, vehicle treatment.
GPRP indicates Gly-Pro-Arg-Pro; FVa and FXa, coagulation factors Va
and Xa, respectively; Vmax, maximum velocity.
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ﬁbrinogen binding to GPIIb-IIIa.
20,21
Enhanced Procoagulant Status Following
Treatment With GPIIb-IIIa Antagonists Alone, and
Ablation by R-138727
The results of previous studies on the effect of GPIIb-IIIa
inhibitors on monocyte–platelet aggregate formation and
tissue factor on monocyte–platelet aggregates are inconsis-
tent, with GPIIb-IIIa inhibitors reported to both augment and
inhibit these processes.
22–25 In agreement with the present
results, separate studies have shown that abciximab
enhanced ADP-induced platelet ﬂuorescence in monocyte–
platelet aggregates,
22 and eptiﬁbatide enhanced tissue factor
expression on monocytes.
23 The enhanced procoagulant
status observed after GPIIb-IIIa antagonist treatment may be
relevant to the increased thrombotic complications observed
with oral GPIIb-IIIa antagonists.
26 In the current study, whole
blood stimulated with collagen plus ADP in the presence of
either abciximab or eptiﬁbatide appears to be in a procoag-
ulant state, as evidenced by increased exposure of tissue
factor antigen on monocyte–platelet aggregates (Figure 5A),
together with an increase in platelet mass associated with
each monocyte (Figure 3B). Indeed, platelet activation–
dependent prothrombinase activity is modestly enhanced in
the presence of eptiﬁbatide (Figure 6). However, abciximab
under the same conditions reduced prothrombinase activity
(Figure 6), thus demonstrating a difference in the ability of
eptiﬁbatide (a 1000 Da, small molecule, reversible GPIIb-IIIa
antagonist) and abciximab (a much larger [50 000 Da], tight-
binding GPIIb-IIIa antagonist) to modulate platelet-dependent
procoagulant activity.
Prothrombin has been shown to bind to GPIIb-IIIa and this
binding accelerates thrombin generation.
27 With its larger
size, abciximab (and other antibody inhibitors) may not only
block prothrombin binding to GPIIb-IIIa but may also sterically
hinder other binding reactions on the platelet surface that are
important for thrombin generation, such as coagulation factor
binding to surface-exposed phosphatidylserine. This concept
is in agreement with a previous study, showing that abciximab
more strongly inhibited annexin V and factor V/Va binding to
the platelet surface than eptiﬁbatide.
28 The molecular size
difference and speciﬁc molecular interactions between each
antagonist and GPIIb-IIIa may explain the variable response in
prothrombin activation. Because tissue factor activation is
modulated by protein disulﬁde-isomerase,
29 it is also tempt-
ing to speculate that eptiﬁbatide and abciximab differentially
affect this activation.
In the present study, the addition of R-138727 to GPIIb-IIIa
antagonists resulted in a signiﬁcant decrease compared with
GPIIb-IIIa inhibitors alone in the percentage of monocyte–
platelet aggregates, tissue factor expression on monocyte–
platelet aggregates, and thrombin generation. This is in
agreement with a previous study on clopidogrel and abciximab
which reported that the addition of clopidogrel to abciximab
treatment ablated the abciximab-induced increase in mono-
cyte–platelet aggregates.
22 Taken together, the presently-
described ablation by prasugrel’s active metabolite of the
GPIIb-IIIa antagonist-induced increase of tissue factor on
monocyte–platelet aggregates and the eptiﬁbatide-induced
increase in thrombin generation, suggests that inhibition of
the platelet P2Y12 ADP receptor may reduce the prothrom-
botic effects of GPIIb-IIIa antagonists.
Study Limitations and Strengths
This study used blood from healthy subjects rather than from
acute coronary syndrome patients, the population for whom
these drugs have an FDA-approved indication, to minimize the
variables of comedications and the degree of disease.
However, all healthy donors were treated with aspirin to
correspond to the clinical conditions where prasugrel and
GPIIb-IIIa antagonists might be coadministered. The power to
detect treatment differences is limited by the small sample
size (n=6); however, signiﬁcant effects of GPIIb-IIIa and/or
P2Y12 inhibition were detected for each end point, even after
application of the conservative Bonferroni correction.
Conclusions
The presently described complementary effects of abciximab
and prasugrel’s active metabolite on collagen plus ADP–
induced platelet activation, aggregation, and procoagulant
activity suggest that the combined use of abciximab and
prasugrelmay,toagreaterdegreethanwitheitheragentalone,
reduce and destabilize thrombus formation in vivo. The GPIIb-
IIIa antagonist-induced increase of tissue factor on monocyte–
platelet aggregates and the eptiﬁbatide-induced increase in
thrombin generation were attenuated by prasugrel’s active
metabolite, suggesting a novel mechanism for reducing the
prothrombotic effects of these GPIIb-IIIa antagonists.
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